LAIETA, TOSCA STEFANIA MARIA
 Distribuzione geografica
Continente #
NA - Nord America 139
AS - Asia 130
EU - Europa 80
SA - Sud America 17
AF - Africa 9
Totale 375
Nazione #
US - Stati Uniti d'America 136
SG - Singapore 48
CN - Cina 26
VN - Vietnam 23
IE - Irlanda 19
SE - Svezia 19
HK - Hong Kong 15
IT - Italia 13
BR - Brasile 11
DE - Germania 9
FI - Finlandia 5
GB - Regno Unito 5
FR - Francia 4
NL - Olanda 3
ZA - Sudafrica 3
BD - Bangladesh 2
IN - India 2
JP - Giappone 2
KE - Kenya 2
MX - Messico 2
PY - Paraguay 2
TR - Turchia 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AR - Argentina 1
AZ - Azerbaigian 1
CA - Canada 1
CO - Colombia 1
DZ - Algeria 1
EC - Ecuador 1
EG - Egitto 1
ES - Italia 1
HU - Ungheria 1
ID - Indonesia 1
IL - Israele 1
LK - Sri Lanka 1
MA - Marocco 1
MY - Malesia 1
PK - Pakistan 1
PS - Palestinian Territory 1
RU - Federazione Russa 1
SN - Senegal 1
SY - Repubblica araba siriana 1
VE - Venezuela 1
Totale 375
Città #
Singapore 33
Chandler 30
Ashburn 25
Dublin 19
Santa Clara 16
Hong Kong 15
Beijing 14
Ho Chi Minh City 9
Hanoi 7
Parma 7
Munich 6
San Jose 5
Shanghai 4
Boardman 3
Bremen 3
Dallas 3
Johannesburg 3
Los Angeles 3
Milan 3
Princeton 3
Turku 3
Ankara 2
Helsinki 2
Mexico City 2
Nairobi 2
Wilmington 2
Amambai 1
Araruama 1
Asunción 1
Baku 1
Bandung 1
Boston 1
Budapest 1
Buffalo 1
Can Tho 1
Casablanca 1
Catarina 1
Changsha 1
Charlotte 1
Chongqing 1
Colombo 1
Columbus 1
Cyberjaya 1
Dakar 1
Damascus 1
Des Moines 1
Didouche Mourad 1
Fairfield 1
Haiphong 1
Hampton 1
Hebron 1
Islamabad 1
La Guaira 1
Lauterbourg 1
Leme 1
Luque 1
Madrid 1
Manaus 1
Matias Barbosa 1
Miami 1
New York 1
Paraná 1
Phoenix 1
Poplar 1
Port Said 1
Porto Alegre 1
Pune 1
Quito 1
Ras al-Khaimah 1
Redwood City 1
Rio Bonito 1
Rockville 1
Rostov-on-Don 1
Sabae 1
Salvador 1
Tampa 1
Tel Aviv 1
The Dalles 1
Timon 1
Tokyo 1
Toronto 1
Vitória 1
Wigan 1
Woodbridge 1
Yerevan 1
Điện Bàn 1
Totale 284
Nome #
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients 137
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: Final results of the phase III randomized Short-HER study 133
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial 108
Totale 378
Categoria #
all - tutte 1.371
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.371


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211 0 0 0 0 0 0 0 0 0 0 1 0
2021/202210 0 0 0 1 0 0 0 0 2 1 1 5
2022/202381 8 11 5 8 8 8 1 8 20 0 0 4
2023/202419 1 1 0 1 2 3 2 1 2 1 1 4
2024/202576 0 5 6 3 6 10 0 3 6 10 7 20
2025/2026166 24 11 12 20 35 11 17 3 18 15 0 0
Totale 378